Mometasone furoate: an effective anti‐inflammatory with a well‐defined safety and tolerability profile in the treatment of asthma

@article{Bousquet2009MometasoneFA,
  title={Mometasone furoate: an effective anti‐inflammatory with a well‐defined safety and tolerability profile in the treatment of asthma},
  author={Jean Bousquet},
  journal={International Journal of Clinical Practice},
  year={2009},
  volume={63}
}
  • J. Bousquet
  • Published 1 May 2009
  • Medicine
  • International Journal of Clinical Practice
Inhaled corticosteroids (ICS) are recommended as a controller medication in the most recent Global Initiative for Asthma and the National Heart, Lung and Blood Institute guidelines. Mometasone furoate (MF) is an effective, well‐tolerated inhaled steroid and is indicated for the maintenance treatment of adult and adolescent patients (≥ 12 years) with persistent asthma. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low… Expand
Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children
TLDR
A wide variety of randomized clinical trials have shown the drug to have a clinically beneficial effect on asthma comparable to fluticasone propionate, and to permit the reduction or withdrawal of oral glucocorticoid therapy in patients with asthma. Expand
A review of mometasone furoate/formoterol in the treatment of asthma
TLDR
The present paper reviews the current knowledge of the novel combination of MF and F for the treatment of asthma and it does not appear from the reviewed literature that MF/F or its individual components are inferior to other equivalent treatments. Expand
Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
TLDR
Triple therapy has been shown to be an effective and safe therapeutic option for asthma patients who remain uncontrolled despite ICS/LABA combination, and the recently approved single-inhaler indacaterol/glycopyrronium/mometasone fixed dose combination has demonstrated to significantly reduce exacerbations, improve FEV1, symptoms and quality of life. Expand
Emerging corticosteroid agonists for the treatment of asthma
Introduction: Asthma is one of the most frequent chronic diseases worldwide. For decades, asthma has been treated with bronchodilators and inhaled corticosteroids (ICS). However, adverse effects ofExpand
The Early Clinical Development of Indacaterol
TLDR
Preclinical data characterizing indacaterol as a long-acting β2-agonist with a sustained 24 h duration of bronchodilation makes it suitable for once-daily dosing, a rapid onset of action and a favourable safety profile over a range of dosages and delivery modes, both in asthma and COPD patients of various severities. Expand
Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats.
TLDR
It is likely that MF/F will have a significant benefit in clinical asthma to suppress lung inflammation and improve lung function and a synergistic interaction between MF and F for reversal of the lung function is demonstrated. Expand
Using Lower Doses of Topical Mometasone Furoate in the Treatment of Atopic Dermatitis by Applying Hyaluronic Acid as a Skin Penetration Enhancer
The objective of the present study was to investigate the possibility to add hyaluronic acid (HA) as skin penetration enhancers to mometasone furoate (MF) to enhance its skin absorption, and soExpand
Local delivery of mometasone furoate from an eluting endotracheal tube
TLDR
The potential of drug‐loaded ETTs to revolutionize the standard of care for endotracheal intubation is demonstrated and an in vivo efficacy study in rats demonstrated the therapeutic benefit of MF‐coated ETTs over bare ETTs. Expand
Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler.
TLDR
PIFR but not Tmax PIFR has an effect on lung deposition after inhalation with an MF-DPI, and FPF for the claimed dose was significantly lower than that at 60 L/min, which was dependent on PifR. Expand
Topical Administration of Mometasone Furoate - A Combined Impedance Spectroscopy and In Vitro Drug Diffusion Study
Mometasone furoate (MF) is a potent steroid for treatment of e.g., eczema and psoriasis. It exerts its function by binding to the glucocorticoid receptors in vi- able epidermis and dermis. The aim ofExpand
...
1
2
3
...

References

SHOWING 1-10 OF 98 REFERENCES
Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids
TLDR
Once-daily evening dosing of MF-DPI at doses of 400 and 200 µg restored lung function and improved nocturnal and daytime symptom control in subjects with asthma previously dependent on bid ICS therapy. Expand
Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
TLDR
This is the first study to demonstrate that a total daily dose of 400 microg of MF administered by means of a DPI is an effective treatment for patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists. Expand
Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
  • A. Nayak, C. Banov, +20 authors J. E. Harrison
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2000
TLDR
The results of this study indicate that once-daily (AM) MF DPI provides a convenient and effective treatment option for patients with mild or moderate persistent asthma. Expand
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
TLDR
Inhaled mometasone furoate is well tolerated, with minimal systemic activity and is equally effective when administered as a divided dose or as a single daily dose. Expand
Effects of Mometasone Furoate Given Once Daily in the Evening on Lung Function and Symptom Control in Persistent Asthma
TLDR
Mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids was as effective in improving pulmonary function, asthma symptoms, and quality of life compared with placebo. Expand
Once-Daily Mometasone Furoate Administered by Dry Powder Inhaler for the Treatment of Children with Persistent Asthma
TLDR
This 12-week, randomized, double-blinded, parallel-group, multicenter trial is the first study to evaluate the efficacy and safety of mometasone furoate administered by pediatric patients once daily in the morning via a novel dry powder inhaler. Expand
Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.
TLDR
MF inhaled orally as a dry powder is an effective alternative to systemic corticosteroids in patients with severe persistent asthma, and Pulmonary function and quality of life significantly increased for MF-treated patients. Expand
Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma.
TLDR
After 12 weeks, despite prednisone reductions, pulmonary function, asthma symptoms, albuterol use, nocturnal awakenings, and physician-evaluated response to therapy also showed significant improvement with MF-MDI treatment compared with placebo. Expand
Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
  • B. O'connor, G. Bonnaud, +4 authors B. Lutsky
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2001
TLDR
A total daily doses of 400 microg of MF-DPI provides clinical benefit comparable to that observed with a total daily dose of 500microg of FP Diskhaler, while a totaldaily 800-microg dose of MF -DPI conferred no significant additional benefit. Expand
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.
TLDR
All doses of mometasone furoate DPI were well tolerated and significantly improved lung function and MF DPI 400 mcg (200 mcg b.i.d.) was the optimal dose in this study of patients with moderate persistent asthma. Expand
...
1
2
3
4
5
...